Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × defactinib × Gynecologic × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 1

Interventions

Paclitaxel 7 pembrolizumab 6 olaparib 5 Carboplatin 4 Bevacizumab 4 tisotumab vedotin 2 niraparib 2 mirvetuximab soravtansine 2 durvalumab 2 Topotecan 2 Taxes 2 Saline Solution 2 Cisplatin 2 sacituzumab govitecan 1 rucaparib 1 liposomal doxorubicin 1 lenvatinib 1 entrectinib 1 defactinib 1 Vinorelbine 1 Pemetrexed 1 Pafolacianine 1 Laparotomy 1 Irinotecan 1 Injections 1 Immunoglobulin G 1 Glucose 1 Gemcitabine 1 Doxorubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04625270 2025-01-29

RAMP 201

Verastem, Inc.

Phase 2 Active not recruiting

225 enrolled 1 FDA

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡